Skip to search formSkip to main contentSkip to account menu

Telcyta

National Institutes of Health

Related topics

Related topics

2 relations
TER 286

Broader (1)

TLK 286

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
The recent full clinical hold placed on trials of canfosfamide [Telcyta]* has been converted to a partial hold by the US FDA
  • 2007
  • Corpus ID: 195171875
2005
2005
Expediting Oncology Drug Approvals: The Public Backlash Against the FDA and Opportunities to Reform
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
2004
2004
Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells.
2008 TLK286 is a novel glutathione analog cancer prodrug that has shown significant antitumor activity in multiple Phase 2… 
2004
2004
GST P1-1 polymorphisms do not affect the rate of TELCYTA™ (TLK286) prodrug activation.
Proc Amer Assoc Cancer Res, Volume 45, 2004 3825 TLK286 is a novel glutathione analog cancer prodrug that has shown… 
2004
2004
Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC)
7140 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1–1, which is overexpressed in NSCLC… 
2004
2004
Phase 1–2a study of TLK286 (a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant (≥ 3rd line) ovarian cancer
5060 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1–1, which is overexpressed in ovarian… 
2004
2004
Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer.
5062 Background: TLK286 (Telcyta) is a glutathione analog prodrug activated by GST P1-1, which is overexpressed in ovarian cancer… 
2004
2004
Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer
5062 Background: TLK286 (Telcyta) is a glutathione analog prodrug activated by GST P1–1, which is overexpressed in ovarian cancer… 
2004
2004
Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC).
7140 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1-1, which is overexpressed in NSCLC… 
Review
2004
Review
2004
TLK 286
TLK 286 [TELCYTA] is an antitumour agent in clinical development with Telik. It was developed through the application of Telik's… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)